Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    23962028 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Exemestane;   Drug: Everolimus Placebo

Indicates status has not been verified in more than two years